대한갑상선학회 갑상선분화암 진료권고안; 개요 및 요약 2024 (Korean Thyroid Association Guidelines on the Management of Differentiated Thyroid Cancers; Overview and Summary 2024)

서지정보

· 발행기관 : 대한갑상선학회
· 수록지 정보 : International Journal of Thyroidology / 17권 / 1호 / 1 ~ 20페이지
· 저자명 : 박영주, 이은경, 송영신, 구본석, 권형주, 김근영, 김미진, 김보현, 김원구, 김원배, 김원웅, 김정한, 김희경, 나희영, 문신제, 문정은, 박소현, 박준욱, 방지인, 백교림, 서영덕, 신동엽, 신수진, 오소원, 우승훈, 원호륜, 유창환, 윤지희, 이가희, 이민경, 이상우, 이승은, 이시훈, 이영아, 이준협, 이지예, 이지은, 이초록, 임동준, 임재열, 전윤경, 정경연, 정아리, 정윤재, 정찬권, 조관훈, 조윤영, 홍아람, 홍채문, 강호철, 김선욱, 정웅윤, 박도준, 나동규, 안화영

초록

Differentiated thyroid cancer demonstrates a wide range of clinical presentations, from very indolent cases to those with an aggressive prognosis. Therefore, diagnosing and treating each cancer appropriately based on its risk status is important. The Korean Thyroid Association (KTA) has provided and amended the clinical guidelines for thyroid cancer management since 2007. The main changes in this revised 2024 guideline include 1) individualization of surgical extent according to pathological tests and clinical findings, 2) application of active surveillance in low-risk papillary thyroid microcarcinoma, 3) indications for minimally invasive surgery, 4) adoption of World Health Organization pathological diagnostic criteria and definition of terminology in Korean, 5) update on literature evidence of recurrence risk for initial risk stratification, 6) addition of the role of molecular testing, 7) addition of definition of initial risk stratification and targeting thyroid stimulating hormone (TSH) concentrations according to ongoing risk stratification (ORS), 8) addition of treatment of perioperative hypoparathyroidism, 9) update on systemic chemotherapy, and 10) addition of treatment for pediatric patients with thyroid cancer.

영어초록

Differentiated thyroid cancer demonstrates a wide range of clinical presentations, from very indolent cases to those with an aggressive prognosis. Therefore, diagnosing and treating each cancer appropriately based on its risk status is important. The Korean Thyroid Association (KTA) has provided and amended the clinical guidelines for thyroid cancer management since 2007. The main changes in this revised 2024 guideline include 1) individualization of surgical extent according to pathological tests and clinical findings, 2) application of active surveillance in low-risk papillary thyroid microcarcinoma, 3) indications for minimally invasive surgery, 4) adoption of World Health Organization pathological diagnostic criteria and definition of terminology in Korean, 5) update on literature evidence of recurrence risk for initial risk stratification, 6) addition of the role of molecular testing, 7) addition of definition of initial risk stratification and targeting thyroid stimulating hormone (TSH) concentrations according to ongoing risk stratification (ORS), 8) addition of treatment of perioperative hypoparathyroidism, 9) update on systemic chemotherapy, and 10) addition of treatment for pediatric patients with thyroid cancer.

참고자료

· 없음